Stock SMSPHARMA SMS PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials SMS Pharmaceuticals Limited

Equities

SMSPHARMA

INE812G01025

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 07:43:49 2024-04-26 am EDT 		5-day change 1st Jan Change
207.4 INR -0.43% Intraday chart for SMS Pharmaceuticals Limited +0.58% +74.77%
Mar. 19 SMS Pharmaceuticals Limited announced that it has received INR 285.75 million in funding from Potluri Infra Projects Private Limited CI
Feb. 09 SMS Pharmaceuticals to Raise Up to INR1.14 Billion from Convertible Warrants MT

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 6,188 5,308 2,277 10,518 7,915 4,931
Enterprise Value (EV) 1 7,523 6,597 3,752 12,660 10,082 7,398
P/E ratio 19.5 x 13.3 x 7.21 x 16.8 x 12.7 x -69.9 x
Yield 0.34% 0.4% 0.93% 0.24% 0.32% 0.52%
Capitalization / Revenue 1.33 x 1.14 x 0.55 x 1.86 x 1.52 x 0.94 x
EV / Revenue 1.62 x 1.41 x 0.91 x 2.24 x 1.94 x 1.42 x
EV / EBITDA 7.96 x 7.16 x 4.58 x 10.3 x 8.83 x 13.7 x
EV / FCF 59.1 x 2,026 x -64.8 x -12.4 x -44.8 x -23.4 x
FCF Yield 1.69% 0.05% -1.54% -8.04% -2.23% -4.27%
Price to Book 2.18 x 1.65 x 0.65 x 2.56 x 1.68 x 1.07 x
Nbr of stocks (in thousands) 84,652 84,652 84,652 84,652 84,652 84,652
Reference price 2 73.10 62.70 26.90 124.2 93.50 58.25
Announcement Date 8/27/18 9/7/19 9/8/20 9/8/21 9/7/22 9/7/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 4,640 4,667 4,146 5,651 5,199 5,221
EBITDA 1 945.2 921.2 819.8 1,227 1,142 541.8
EBIT 1 747.6 729.5 609.7 1,014 830.7 227.3
Operating Margin 16.11% 15.63% 14.71% 17.95% 15.98% 4.35%
Earnings before Tax (EBT) 1 516.4 609.5 496.4 926.8 628.4 -55.94
Net income 1 317.5 400.5 315.7 625.3 622.2 -70.59
Net margin 6.84% 8.58% 7.62% 11.06% 11.97% -1.35%
EPS 2 3.751 4.731 3.730 7.386 7.350 -0.8339
Free Cash Flow 1 127.2 3.256 -57.89 -1,018 -224.8 -315.8
FCF margin 2.74% 0.07% -1.4% -18.02% -4.32% -6.05%
FCF Conversion (EBITDA) 13.46% 0.35% - - - -
FCF Conversion (Net income) 40.07% 0.81% - - - -
Dividend per Share 2 0.2500 0.2500 0.2500 0.3000 0.3000 0.3000
Announcement Date 8/27/18 9/7/19 9/8/20 9/8/21 9/7/22 9/7/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 1,335 1,290 1,475 2,142 2,167 2,467
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 1.412 x 1.4 x 1.8 x 1.746 x 1.897 x 4.553 x
Free Cash Flow 1 127 3.26 -57.9 -1,018 -225 -316
ROE (net income / shareholders' equity) 11.8% 13.2% 9.42% 16.5% 14.1% -1.52%
ROA (Net income/ Total Assets) 9.39% 8.59% 6.53% 8.93% 6.21% 1.63%
Assets 1 3,383 4,661 4,833 7,003 10,017 -4,322
Book Value Per Share 2 33.60 38.00 41.10 48.50 55.60 54.40
Cash Flow per Share 2 1.490 1.750 1.130 4.780 5.500 0.8700
Capex 1 85.5 348 427 1,517 272 299
Capex / Sales 1.84% 7.46% 10.31% 26.85% 5.24% 5.73%
Announcement Date 8/27/18 9/7/19 9/8/20 9/8/21 9/7/22 9/7/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
SMS PHARMACEUTICALS LIMITED Stock SMS Pharmaceuticals Limited
+74.77% 211M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.62% 43.34B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.44% 21.96B
SANDOZ GROUP AG Stock Sandoz Group AG
+10.86% 14.09B
CIPLA LIMITED Stock Cipla Limited
+13.07% 13.64B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+37.46% 11.43B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.59% 6.86B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+8.46% 5.22B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SMSPHARMA Stock
  4. Financials SMS Pharmaceuticals Limited